Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Somatostatin agonists for treatment of acromegaly.

Literature DB >> 18191325

Somatostatin agonists for treatment of acromegaly.

Abstract

The discovery of somatotropin-release inhibitory factor (SRIF) in hypothalamic extract in 1970 led to the synthesis of the first somatostatin analog octreotide, discovery of five somatostatin receptor subtypes, and development of additional somatostatin receptor ligands (SRL) as pharmacotherapy for acromegaly and other neuroendocrine tumors. Long-acting formulations of SRL (octreotide LAR Depot, lanreotide SR and lanreotide autogel) assure improved patient compliance with weekly up to monthly injections, and are commonly used as primary or adjuvant treatment of acromegaly. We review SRL currently available, emphasizing long-acting compounds and their efficacy in controlling acromegaly. Disease control is evaluated by biochemical markers, tumor shrinkage, and disease-symptom improvement balanced against drug-related side effects.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 18191325 PMCID： PMC2697610 DOI： 10.1016/j.mce.2007.11.024

Source DB: PubMed Journal: Mol Cell Endocrinol ISSN： 0303-7207 Impact factor: 4.102

64 in total

1. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.

Authors: John Ayuk; Susan E Stewart; Paul M Stewart; Michael C Sheppard
Journal: J Clin Endocrinol Metab Date: 2002-09 Impact factor: 5.958

Review 2. Somatostatin analogs in acromegaly.

Authors: Pamela U Freda
Journal: J Clin Endocrinol Metab Date: 2002-07 Impact factor: 5.958

3. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.

Authors: Giovanni Amato; Gherardo Mazziotti; Mario Rotondi; Sergio Iorio; Mauro Doga; Francesca Sorvillo; Giovanni Manganella; Francesco Di Salle; Andrea Giustina; Carlo Carella
Journal: Clin Endocrinol (Oxf) Date: 2002-01 Impact factor: 3.478

4. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.

Authors: Maria Rosaria Ambrosio; Paola Franceschetti; Marta Bondanelli; Mauro Doga; Pietro Maffei; Roberto Baldelli; Guido Tamburrano; Nicola Sicolo; Andrea Giustina; Ettore C degli Uberti
Journal: Metabolism Date: 2002-03 Impact factor: 8.694

5. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity.

Authors: M S Ip; K C Tan; W C Peh; K S Lam
Journal: Clin Endocrinol (Oxf) Date: 2001-10 Impact factor: 3.478

Review 6. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.

Authors: Patrick Maison; Anne-Isabelle Tropeano; Isabelle Macquin-Mavier; Andrea Giustina; Philippe Chanson
Journal: J Clin Endocrinol Metab Date: 2007-02-20 Impact factor: 5.958

7. Effects of two different somatostatin analogs on glucose tolerance in acromegaly.

Authors: C Ronchi; P Epaminonda; V Cappiello; P Beck-Peccoz; M Arosio
Journal: J Endocrinol Invest Date: 2002-06 Impact factor: 4.256

8. Cardiovascular consequences of early-onset growth hormone excess.

Authors: Annamaria Colao; Letizia Spinelli; Alberto Cuocolo; Stefano Spiezia; Rosario Pivonello; Carolina di Somma; Domenico Bonaduce; Marco Salvatore; Gaetano Lombardi
Journal: J Clin Endocrinol Metab Date: 2002-07 Impact factor: 5.958

9. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.

Authors: G Lombardi; A Colao; P Marzullo; B Biondi; E Palmieri; S Fazio
Journal: J Endocrinol Invest Date: 2002-12 Impact factor: 4.256

10. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Authors: J S Bevan; S L Atkin; A B Atkinson; P-M Bouloux; F Hanna; P E Harris; R A James; M McConnell; G A Roberts; M F Scanlon; P M Stewart; E Teasdale; H E Turner; J A H Wass; J M Wardlaw
Journal: J Clin Endocrinol Metab Date: 2002-10 Impact factor: 5.958

30 in total

Review 1. Acromegaly.

Authors: Anat Ben-Shlomo; Shlomo Melmed
Journal: Endocrinol Metab Clin North Am Date: 2008-03 Impact factor: 4.741

Review 2. Somatostatin receptor ligands in the treatment of acromegaly.

Authors: Monica R Gadelha; Luiz Eduardo Wildemberg; Marcello D Bronstein; Federico Gatto; Diego Ferone
Journal: Pituitary Date: 2017-02 Impact factor: 4.107

3. Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.

Authors: F Bogazzi; G Rossi; M Lombardi; F Raggi; C Urbani; C Sardella; C Cosci; E Martino
Journal: J Endocrinol Invest Date: 2010-07-29 Impact factor: 4.256

Review 4. The changing face of acromegaly--advances in diagnosis and treatment.

Authors: Antônio Ribeiro-Oliveira; Ariel Barkan
Journal: Nat Rev Endocrinol Date: 2012-06-26 Impact factor: 43.330

5. Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center.

Authors: Babak Torabi Sagvand; Shafaq Khairi; Arezoo Haghshenas; Brooke Swearingen; Nicholas A Tritos; Karen K Miller; Anne Klibanski; Lisa B Nachtigall
Journal: Pituitary Date: 2016-08 Impact factor: 4.107

Review 6. Pituitary somatostatin receptor signaling.

Authors: Anat Ben-Shlomo; Shlomo Melmed
Journal: Trends Endocrinol Metab Date: 2010-02-09 Impact factor: 12.015

7. Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient.

Authors: Daphne D Dadzie; Esther J Lee; Catherine A Monteleone; Stephen H Schneider
Journal: Pituitary Date: 2012-12 Impact factor: 4.107

Review 8. Medical therapy of acromegaly in Turkey.

Authors: O Celik; P Kadioglu
Journal: J Endocrinol Invest Date: 2010-09 Impact factor: 4.256

9. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.

Authors: Lucio Vilar; Monalisa F Azevedo; Luciana Ansaneli Naves; Luiz Augusto Casulari; José Luciano Albuquerque; Renan M Montenegro; Renan M Montenegro; Patricia Figueiredo; Gilvan C Nascimento; Manuel S Faria
Journal: Pituitary Date: 2011-06 Impact factor: 4.107

10. Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism.

Authors: Sneha Singh; Rishi K Somvanshi; Vandana Panda; Ujendra Kumar
Journal: Endocrine Date: 2020-04-25 Impact factor: 3.633